VANCOUVER, Canada I May 19, 2025 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...

BOSTON, MA, USA I May 19, 2025 I Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

Clinical data of Cytora's oral mucosa stem cells treatment shown to be safe and may be efficient as a disease modifying therapy in moderate stages of Multiple ...

GAITHERSBURG, MD, USA I May 19, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

NEW YORK, NY, USA I May 19, 2025 I Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, ...

Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – ...

CAMBRIDGE, MA, USA I May 17, 2025 I Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell ...

SHANGHAI, China I May 15, 2025 I Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of ...

A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation While GLP-1 receptor agonists (e.g., semaglutide, tirzepatide ...

SAN RAFAEL, CA and BOSTON, MA, USA I May 16, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced today that BioMarin has entered into a definitive ...